CClinicalTrials.gg
Not yet recruitingNCT07833865PBM-T1DUpdated Sep 25, 2026

The Effect of Light Therapy on Cellular Energy and Oxidative Stress in Healthy Adults and Type 1 Diabetic Patients

An interventional study of Red and Near-Infrared Light Therapy Pad in Healthy and Diabetes Mellitus Type 1, sponsored by University of Thi-Qar. Not yet recruiting at 1 site in Iraq. Open to participants aged 12 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by University of Thi-Qar · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
12 Years to 40 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the effects of low-level light therapy on cellular energy and oxidative stress in healthy adults and patients with Type 1 diabetes. The main questions it aims to answer are:

Does light therapy change adenosine triphosphate (ATP) levels and cytochrome c oxidase activity in blood cells? How does the intervention affect oxidative stress markers, specifically glutathione and malondialdehyde concentrations? Researchers will compare blood samples collected before the light therapy to those collected afterward to see if the intervention alters mitochondrial function. Researchers will also compare the responses of healthy volunteers to those of diabetic patients.

Participants will:

Provide a baseline blood sample. Receive red and near-infrared light exposure (660 nm and 850 nm) on their arms for 10 to 20 minutes using a therapy pad.

Provide a final blood sample immediately after the light exposure.

Read the detailed description

This study evaluates the metabolic effects of photobiomodulation on peripheral blood mononuclear cells in patients with Type 1 diabetes and healthy volunteers. The intervention applies red (660 nm) and near-infrared (850 nm) light to stimulate cytochrome c oxidase within the mitochondrial electron transport chain. This photon absorption increases cellular respiration and alters oxidative stress markers.

Researchers collect baseline venous blood samples from all participants to establish initial biochemical parameters. The clinical team isolates peripheral blood mononuclear cells using density gradient centrifugation. Following baseline collection, participants receive a single 10-to-20-minute light therapy session on the upper arm using a flexible light pad. Researchers collect a second venous blood sample immediately after the light exposure.

The laboratory analysis quantifies specific mitochondrial and metabolic variables in the cell lysates before and after the intervention. The primary metrics are adenosine triphosphate (ATP) concentration and cytochrome c oxidase specific activity. Secondary measures include malondialdehyde and glutathione to assess lipid peroxidation and antioxidant capacity. The research team also measures lactate and pyruvate levels to evaluate shifts in cellular glycolysis, alongside standard fasting plasma glucose monitoring. The comparative analysis evaluates differences in metabolic response between the diabetic cohort and the healthy matched controls.

02

Conditions studied

  • Healthy
  • Diabetes Mellitus Type 1

Keywords

  • Photobiomodulation
  • Malondialdehyde
  • Glutathione
  • Mitochondria
  • Cytochrome c Oxidase
  • Adenosine Triphosphate
  • Oxidative Stress
  • Low-Level Light Therapy
03

Who can participate

Ages eligible
12 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 12 to 40 years.
  • Confirmed diagnosis of Type 1 Diabetes Mellitus based on American Diabetes Association criteria (patient group).
  • Insulin dependence (patient group).
  • Low serum C-peptide levels (patient group).
  • Fasting plasma glucose concentration \<100 mg/dL (healthy control group).
  • Glycated haemoglobin (HbA1c) \<5.7% (healthy control group).
  • Diabetes duration of at least 1 year (patient group).

Exclusion criteria

Exclusion Criteria:

  • Diabetic ketoacidosis within the preceding month.
  • High-sensitivity C-reactive protein (hs-CRP) >10 mg/L or active infection.
  • Renal insufficiency.
  • Liver disease.
  • Pregnancy.
  • Smoking.
  • Use of antioxidant supplements, vitamin C, or vitamin E within the preceding month.
  • Autoimmune diseases other than Type 1 Diabetes Mellitus.
  • Haematological disorders.
04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Photobiomodulation Intervention

    Researchers apply the photobiomodulation device to the arm of every enrolled participant, encompassing both the healthy volunteers and the patients diagnosed with Type 1 diabetes, for a strictly timed session lasting between 10 and 20 minutes.

    Device: Red and Near-Infrared Light Therapy Pad

Interventions

  • DeviceRed and Near-Infrared Light Therapy Pad

    Participants receive a single photobiomodulation session using a flexible light therapy pad. The device delivers red light at 660 nm and near-infrared light at 850 nm with an operating voltage of 5V and a working current of 1.7A. The pad is placed in direct contact with the upper arm of each participant for a timed duration of 10 to 20 minutes. Researchers evaluate cellular responses before and immediately after this single application.

05

What researchers measure

Primary outcomes

  1. Change in Adenosine Triphosphate (ATP) Concentration

    Researchers measure ATP levels in blood cells using a specific assay kit to evaluate cellular energy production.

    Time frame: Baseline and immediately after the 10-to-20-minute light therapy session

  2. Change in Cytochrome c Oxidase Activity

    Researchers assess the specific activity of cytochrome c oxidase in blood samples via a biochemical assay to determine mitochondrial function.

    Time frame: Baseline and immediately after the 10-to-20-minute light therapy session

Secondary outcomes

  1. Change in Malondialdehyde (MDA) Levels

    Researchers quantify MDA concentration in the collected blood samples to assess oxidative stress.

    Time frame: Baseline and immediately after the 10-to-20-minute light therapy session

  2. Change in Lactate and Pyruvate Concentrations

    Researchers determine the concentrations of lactate and pyruvate in blood cells to analyze metabolic shifts.

    Time frame: Baseline and immediately after the 10 to 20-minute light therapy session

  3. Change in Glutathione (GSH) Levels

    Researchers measure glutathione concentration in the blood samples to evaluate antioxidant capacity.

    Time frame: Baseline and immediately after the 10-to-20-minute light therapy session

  4. Change in Blood Glucose Levels

    Researchers measure blood glucose concentrations in the collected blood samples to evaluate glycemic changes following the light therapy session.

    Time frame: Baseline and immediately after the 10-to-20-minute light therapy session

06

Study locations

1 site
  • Thi-Qar Specialized Diabetes, Endocrine and Metabolism Center (TDEMC)
    Nasiriyah, TQ 64001, Iraq
07

References and documents

Individual participant data

Plan to share: Yes — All individual participant data (IPD) that underlie the results reported in the published article will be shared after complete de-identification. This includes demographic characteristics and all measured biochemical variables (ATP concentration, cytochrome c oxidase activity, malondialdehyde, glutathione, lactate, pyruvate, and blood glucose) collected at baseline and immediately following the light therapy session.

Supporting information: Study protocol, Sap, Analytic code

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07833865
Lead sponsor
University of Thi-Qar
Responsible party
Joudi Shaker (MSc Researcher, University of Thi-Qar) — Principal investigator
First posted
Sep 22, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Jan 15, 2027 (estimated)
Completion
Jan 15, 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Joudi k. Shaker, MSc
Contact
j.shaker@utq.edu.iq
+964-780-630-0739
Hattf B. Farhood, PhD
study director · University of Thi-Qar

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion